In this scenario, the lack of PTEN anticancer control could play a pivotal role by favoring cellular proliferation and survival, in turn allowing the accumulation of additional genetic events towards leukemogenesis, as suggested by the latency between expression of the hybrid protein and leukemia onset in PML/RARA transgenic mice [6, 9]. Here, PML is linked to leukemia.